These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37778239)

  • 1. Inhibition of Son of Sevenless Homologue 1 (SOS1): Promising therapeutic treatment for KRAS-mutant cancers.
    Chen T; Tang X; Wang Z; Feng F; Xu C; Zhao Q; Wu Y; Sun H; Chen Y
    Eur J Med Chem; 2023 Dec; 261():115828. PubMed ID: 37778239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of Son of Sevenless Homologue 1 (SOS1) Modulators To Treat Cancers by Regulating RAS Signaling.
    Luo G; Wang B; Hou Q; Wu X
    J Med Chem; 2023 Apr; 66(7):4324-4341. PubMed ID: 36987571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Son of Sevenless 1: The pacemaker of KRAS.
    Kessler D; Gerlach D; Kraut N; McConnell DB
    Curr Opin Chem Biol; 2021 Jun; 62():109-118. PubMed ID: 33848766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading.
    Sudhakar N; Yan L; Qiryaqos F; Engstrom LD; Laguer J; Calinisan A; Hebbert A; Waters L; Moya K; Bowcut V; Vegar L; Ketcham JM; Ivetac A; Smith CR; Lawson JD; Rahbaek L; Clarine J; Nguyen N; Saechao B; Parker C; Elliott AJ; Vanderpool D; He L; Hover LD; Fernandez-Banet J; Coma S; Pachter JA; Hallin J; Marx MA; Briere DM; Christensen JG; Olson P; Haling J; Khare S
    Mol Cancer Ther; 2024 Oct; 23(10):1418-1430. PubMed ID: 38904222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of PROTACS degrading KRAS and SOS1.
    Hamilton G; Eggerstorfer MT; Stickler S
    Oncol Res; 2024; 32(8):1257-1264. PubMed ID: 39055890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and Structure-Based Optimization of Benzimidazole-Derived Activators of SOS1-Mediated Nucleotide Exchange on RAS.
    Hodges TR; Abbott JR; Little AJ; Sarkar D; Salovich JM; Howes JE; Akan DT; Sai J; Arnold AL; Browning C; Burns MC; Sobolik T; Sun Q; Beesetty Y; Coker JA; Scharn D; Stadtmueller H; Rossanese OW; Phan J; Waterson AG; McConnell DB; Fesik SW
    J Med Chem; 2018 Oct; 61(19):8875-8894. PubMed ID: 30205005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting RAS oncogenesis with SOS1 inhibitors.
    Hillig RC; Bader B
    Adv Cancer Res; 2022; 153():169-203. PubMed ID: 35101230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct inhibition of oncogenic KRAS by hydrocarbon-stapled SOS1 helices.
    Leshchiner ES; Parkhitko A; Bird GH; Luccarelli J; Bellairs JA; Escudero S; Opoku-Nsiah K; Godes M; Perrimon N; Walensky LD
    Proc Natl Acad Sci U S A; 2015 Feb; 112(6):1761-6. PubMed ID: 25624485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translational relevance of SOS1 targeting for KRAS-mutant colorectal cancer.
    Alem D; Yang X; Beato F; Sarcar B; Tassielli AF; Dai R; Hogenson TL; Park MA; Jiang K; Cai J; Yuan Y; Fernandez-Zapico ME; Tan AC; Fleming JB; Xie H
    Mol Carcinog; 2023 Jul; 62(7):1025-1037. PubMed ID: 37042566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cereblon-based Bifunctional Degrader of SOS1, BTX-6654, Targets Multiple KRAS Mutations and Inhibits Tumor Growth.
    Begovich K; Schoolmeesters A; Rajapakse N; Martinez-Terroba E; Kumar M; Shakya A; Lai C; Greene S; Whitefield B; Okano A; Mali V; Huang S; Chourasia AH; Fung L
    Mol Cancer Ther; 2024 Apr; 23(4):407-420. PubMed ID: 38224565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction.
    Hillig RC; Sautier B; Schroeder J; Moosmayer D; Hilpmann A; Stegmann CM; Werbeck ND; Briem H; Boemer U; Weiske J; Badock V; Mastouri J; Petersen K; Siemeister G; Kahmann JD; Wegener D; Böhnke N; Eis K; Graham K; Wortmann L; von Nussbaum F; Bader B
    Proc Natl Acad Sci U S A; 2019 Feb; 116(7):2551-2560. PubMed ID: 30683722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-throughput screening identifies small molecules that bind to the RAS:SOS:RAS complex and perturb RAS signaling.
    Burns MC; Howes JE; Sun Q; Little AJ; Camper DV; Abbott JR; Phan J; Lee T; Waterson AG; Rossanese OW; Fesik SW
    Anal Biochem; 2018 May; 548():44-52. PubMed ID: 29444450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of Orally-bioavailable Tetra-cyclic phthalazine SOS1 inhibitors with high selectivity against EGFR.
    He H; Chen R; Wang Z; Qing L; Zhang Y; Liu Y; Pan W; Fang H; Zhang S
    Bioorg Chem; 2023 Jul; 136():106536. PubMed ID: 37054529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of Orally Bioavailable SOS1 Inhibitors for Suppressing KRAS-Driven Carcinoma.
    He H; Zhang Y; Xu J; Li Y; Fang H; Liu Y; Zhang S
    J Med Chem; 2022 Oct; 65(19):13158-13171. PubMed ID: 36173339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small molecule Son of Sevenless 1 (SOS1) inhibitors: a review of the patent literature.
    Thompson SK; Buckl A; Dossetter AG; Griffen E; Gill A
    Expert Opin Ther Pat; 2021 Dec; 31(12):1189-1204. PubMed ID: 34253125
    [No Abstract]   [Full Text] [Related]  

  • 16. One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRAS.
    Ramharter J; Kessler D; Ettmayer P; Hofmann MH; Gerstberger T; Gmachl M; Wunberg T; Kofink C; Sanderson M; Arnhof H; Bader G; Rumpel K; Zöphel A; Schnitzer R; Böttcher J; O'Connell JC; Mendes RL; Richard D; Pototschnig N; Weiner I; Hela W; Hauer K; Haering D; Lamarre L; Wolkerstorfer B; Salamon C; Werni P; Munico-Martinez S; Meyer R; Kennedy MD; Kraut N; McConnell DB
    J Med Chem; 2021 May; 64(10):6569-6580. PubMed ID: 33719426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation.
    Sheffels E; Sealover NE; Wang C; Kim DH; Vazirani IA; Lee E; M Terrell E; Morrison DK; Luo J; Kortum RL
    Sci Signal; 2018 Sep; 11(546):. PubMed ID: 30181243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unique dependence on Sos1 in
    You X; Kong G; Ranheim EA; Yang D; Zhou Y; Zhang J
    Blood; 2018 Dec; 132(24):2575-2579. PubMed ID: 30377195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and bioevaluation of SOS1 PROTACs derived from pyrido[2,3-d]pyrimidin-7-one-based SOS1 inhibitor.
    Wang K; Zhou Z; Ma X; Xu J; Xu W; Zhou G; Zhou C; Li H; Zheng M; Zhang S; Xu T
    Bioorg Med Chem Lett; 2024 Jul; 107():129780. PubMed ID: 38714262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of Five SOS2 Fragment Hits with Binding Modes Determined by SOS2 X-Ray Cocrystallography.
    Smith CR; Chen D; Christensen JG; Coulombe R; Féthière J; Gunn RJ; Hollander J; Jones B; Ketcham JM; Khare S; Kuehler J; Lawson JD; Marx MA; Olson P; Pearson KE; Ren C; Tsagris D; Ulaganathan T; Van't Veer I; Wang X; Ivetac A
    J Med Chem; 2024 Jan; 67(1):774-781. PubMed ID: 38156904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.